- Home
- LUNG vs VNDA Comparison
LUNG vs VNDA Comparison
Compare LUNG & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LUNG
- VNDA
- Stock Information
- Founded
- LUNG 1995
- VNDA 2002
- Country
- LUNG United States
- VNDA United States
- Employees
- LUNG N/A
- VNDA N/A
- Industry
- LUNG Industrial Specialties
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- LUNG Health Care
- VNDA Health Care
- Exchange
- LUNG Nasdaq
- VNDA Nasdaq
- Market Cap
- LUNG 124.0M
- VNDA 261.7M
- IPO Year
- LUNG 2020
- VNDA 2006
- Fundamental
- Price
- LUNG $2.87
- VNDA $4.78
- Analyst Decision
- LUNG Buy
- VNDA Strong Buy
- Analyst Count
- LUNG 6
- VNDA 3
- Target Price
- LUNG $11.53
- VNDA $15.33
- AVG Volume (30 Days)
- LUNG 317.8K
- VNDA 408.4K
- Earning Date
- LUNG 07-30-2025
- VNDA 07-30-2025
- Dividend Yield
- LUNG N/A
- VNDA N/A
- EPS Growth
- LUNG N/A
- VNDA N/A
- EPS
- LUNG N/A
- VNDA N/A
- Revenue
- LUNG $87,473,000.00
- VNDA $201,351,000.00
- Revenue This Year
- LUNG $18.02
- VNDA $16.86
- Revenue Next Year
- LUNG $18.17
- VNDA $39.78
- P/E Ratio
- LUNG N/A
- VNDA N/A
- Revenue Growth
- LUNG 19.84
- VNDA 13.37
- 52 Week Low
- LUNG $2.50
- VNDA $3.81
- 52 Week High
- LUNG $9.37
- VNDA $6.37
- Technical
- Relative Strength Index (RSI)
- LUNG 39.07
- VNDA 53.88
- Support Level
- LUNG $2.62
- VNDA $4.85
- Resistance Level
- LUNG $2.88
- VNDA $5.12
- Average True Range (ATR)
- LUNG 0.17
- VNDA 0.18
- MACD
- LUNG 0.05
- VNDA 0.01
- Stochastic Oscillator
- LUNG 39.68
- VNDA 54.05
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.